Síndrome de Miller Fisher, un desafío diagnóstico de oftalmoplejía: reporte de un caso / Miller Fisher syndrome, a diagnostic challenge of ophthalmoplegia: a case report

El síndrome de Guillain-Barré (SGB), y sus derivados, entre ellos el síndrome de Miller Fisher (SMF); junto a otras patologías de origen neurológico como la Polineuropatía desmielinizante inflamatoria crónica (CIDP), las polineuropatías de causa metabólica, miastenia gravis, esclerosis lateral amiotrófica (ELA), síndrome de Lambert-Eaton, encefalopatía de Wernicke entre otras; presentan signos y síntomas neurológicos de presentación común. De este modo, la importancia del examen neurológico acabado; y los exámenes de apoyo diagnóstico como: laboratorio -destacando el líquido cefalorraquídeo (LCR)-, electromiografía, y toma de imágenes, son cruciales para esclarecer el diagnóstico. Así, es posible ofrecer un tratamiento de forma precoz, basado en la evidencia, y con el objetivo de disminuir la letalidad de la enfermedad. En el presente texto se plasma un subgrupo de patología de SGB, el SMF, el cual posee una incidencia significativamente baja, una clínica característica, y un pronóstico bastante ominoso sin un tratamiento adecuado. En el presente texto se plasma el reporte de un caso abordado en el Hospital San Pablo de Coquimbo, Chile.

Guillain-Barré syndrome (GBS) and its derivatives, including Miller Fisher syndrome (MFS), along others pathologies of neurological origin such as chronic inflammatory demyelinating polyneuropathy (CIDP), metabolic polyneuropathies, myasthenia gravis, amyotrophic lateral sclerosis (ALS), Lambert-Eaton syndrome, Wernicke's encephalopathy and well as others, have common neurological signs and symptoms. In this way, the importance of a thorough neurological examination, and supporting diagnostic tests such as: laboratory, -cerebrospinal fluid (CSF)-electromyography, and imaging, are crucial to clarify the diagnosis. Thus, it is possible to offer early, evidence-based treatment with an aim of reducing the disease's lethality. In the text below we present a subgroup of GBS pathology, MFS, which has a significantly low incidence, a characteristic clinical picture, and a rather ominous prognosis without adequate treatment. In the following text/paper is shown the report of a case approached in San Pablo Hospital, from Coquimbo, Chile.

Sindrome de Guillain-Barre variante axonal en pediatria: reporte de caso / Guillain-Barre Syndrome axonal variant in pediatrics: case report

RESUMEN El síndrome de Guillain-Barré es una polirradiculoneuropatía inflamatoria aguda, caracterizada por debilidad simétrica de carácter progresivo, de inicio distal asociado con arreflexia y síntomas sensitivos leves. La variante NMAA es una entidad poco frecuente en América Latina. Se reporta el caso de un paciente de sexo masculino, de seis años, previamente sano, con diagnóstico de síndrome de Guillain-Barré variante axonal, secundario a cuadro de vías aéreas superiores. La importancia del reporte radica en informar al pediatra y a otros profesionales de la salud acerca de la existencia de esta entidad y así aumentar la sospecha diagnóstica, considerando su baja incidencia. Se destaca también la posibilidad de encontrar variabilidad en las formas clínicas típicas de presentación, como lo fue el caso presentado, ya que es un subtipo de la enfermedad que está clásicamente caracterizada como grave, de evolución tórpida y con frecuentes secuelas.

SUMMARY Guillain-Barre syndrome is an acute inflammatory polyradiculoneuropathy characterized by progressive symmetric weakness of distal onset associated with areflexia and mild sensory symptoms. The AMAN variant is a rare entity in Latin America. The case of a 6-year-old male patient, previously healthy, with a diagnosis of Guillain-Barre Syndrome, axonal variant, secondary to upper airway symptoms, is reported. The importance of the report lies in informing the pediatrician and other health professionals about the existence of this entity and thus increasing the diagnostic suspicion considering its low incidence. We also highlight the possibility of finding variability in the typical clinical forms of presentation, as was the case presented, since it is a subtype of the disease that is classically characterized as severe and with torpid evolution. It is also associated with frequent sequelae.

Anti-Enteric Neuronal Antibodies and the Irritable Bowel Syndrome

BACKGROUND/AIMS: Functional gastrointestinal disorders are those in which no abnormal metabolic or physical processes, which can account for the symptoms, can be identified. The irritable bowel syndrome (IBS) is a significant functional disorder, which affects 10-20 percent of the population worldwide. Predominant symptoms of IBS are abnormal defecation associated with abdominal pain, both of which may be exacerbated by psychogenic stress. Our study was designed to test a hypothesis that symptoms in a subset of patients with a diagnosis of IBS are associated with an autoimmune degenerative neuropathy in the enteric nervous system. METHODS: Serum was collected from Rome II-IBS patients and controls at the University of North Carolina Functional Gastrointestinal Diseases Center. Assay procedures were immunohistochemical localization of antibody binding to enteric neurons and human protein microarray assay for antigens recognized by antibodies in the sera. RESULTS: Eighty-seven percent of IBS sera and 59% of control sera contained anti-enteric neuronal antibodies. Antibody immunostaining was seen in the nucleus and cytoplasm of neurons in the enteric nervous system. Protein microarray analysis detected antibody reactivity for autoantigens in serum with anti-enteric neuronal antibodies and no reactivity for the same autoantigens in samples not containing anti-enteric neuronal antibodies in our immunostaining assay. Antibodies in sera from IBS patients recognized only 3 antigens out of an 8,000 immunoprotein array. The 3 antigens were: (1) a nondescript ribonucleoprotein (RNP-complex); (2) small nuclear ribonuclear polypeptide A; and (3) Ro-5,200 kDa. CONCLUSIONS: Results of the present study suggest that symptoms in a subset of IBS patients might be a reflection of enteric neuronal damage or loss, caused by circulating anti-enteric autoimmune antibodies.